| scholarly article | Q13442814 |
| P50 | author | Seppo Ylä-Herttuala | Q11893052 |
| Kristiina Tyynelä | Q125255928 | ||
| Gillian Langford | Q125257061 | ||
| P2093 | author name string | Ritva Vanninen | |
| Arto Immonen | |||
| Neil Murray | |||
| Matti Vapalahti | |||
| Anu Sandmair | |||
| Heleena Hurskainen | |||
| P2860 | cites work | Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas | Q34361481 |
| Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo | Q35152561 | ||
| Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses | Q40611932 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model | Q44184297 | ||
| Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir | Q44466935 | ||
| Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses | Q44654746 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions | Q45743137 | ||
| A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 | ||
| 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. | Q45863255 | ||
| Adenovirus-mediated gene therapy of experimental gliomas | Q45870226 | ||
| Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. | Q45878724 | ||
| Sensitivity and reproducibility in adenoviral infectious titer determination | Q45882539 | ||
| Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 | ||
| Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. | Q54635100 | ||
| A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma | Q58659735 | ||
| Cancer gene therapy — current status in the clinics | Q59703813 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 967-972 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study | |
| P478 | volume | 10 |
| Q39739254 | A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells |
| Q36158701 | A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. |
| Q33877450 | A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics |
| Q64376835 | A phase I trial of Ad.hIFN-beta gene therapy for glioma |
| Q41769012 | A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model |
| Q26849375 | A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme |
| Q41963078 | Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy |
| Q36419822 | Adenoviral vectors--how to use them in cancer gene therapy? |
| Q37223846 | Adenoviral virotherapy for malignant brain tumors |
| Q36172992 | Adenoviral-mediated gene transfer into the canine brain in vivo |
| Q34506962 | Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma |
| Q42284125 | Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial |
| Q45871162 | Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells |
| Q37316842 | An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors |
| Q39308911 | An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance |
| Q33551268 | Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression |
| Q37710089 | Avidin-biotin technology in targeted therapy |
| Q36740261 | Baculovirus: an insect-derived vector for diverse gene transfer applications |
| Q38685603 | Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors |
| Q39965334 | Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. |
| Q37634940 | Bystander or no bystander for gene directed enzyme prodrug therapy |
| Q33711997 | Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5. |
| Q53074821 | Cancer Vaccines in Glioma: How to Balance the Challenges of Small Trials, Efficiency, and Potential Adverse Events |
| Q36519055 | Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect |
| Q34027421 | Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect |
| Q46945028 | Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury |
| Q38194340 | Cardiac to cancer: connecting connexins to clinical opportunity. |
| Q50977875 | Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy. |
| Q45876668 | Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies |
| Q43898698 | Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy |
| Q38265614 | Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma |
| Q34782295 | Clinical development of experimental therapies for malignant glioma. |
| Q36367428 | Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas |
| Q38153777 | Clinical trials of viral therapy for malignant gliomas |
| Q34115068 | Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. |
| Q36058012 | Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer |
| Q45886735 | Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma |
| Q45883534 | Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results |
| Q58797848 | Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials |
| Q38800411 | Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification |
| Q36823697 | Current status of cardiovascular gene therapy |
| Q38072814 | Current status of immunotherapy and gene therapy for high-grade gliomas |
| Q37861631 | Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development |
| Q45862926 | E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models |
| Q42876305 | ESCGT 2008: progress in clinical gene therapy |
| Q35118919 | Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. |
| Q37730116 | Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma |
| Q102063578 | Effects of oncolytic viruses and viral vectors on immunity in glioblastoma |
| Q36658314 | Efficacy of nonviral gene transfer in the canine brain |
| Q45411954 | Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors |
| Q40223019 | Enriching suicide gene bearing tumor cells for an increased bystander effect |
| Q38789667 | Exogenous p53 and ASPP2 expression enhances rAdV-TK/ GCV-induced death in hepatocellular carcinoma cells lacking functional p53 |
| Q40208813 | Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q37010979 | Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. |
| Q36994063 | Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. |
| Q30434475 | Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology |
| Q45872003 | Gap junctions in human glioblastomas: implications for suicide gene therapy |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q51846343 | Gene Therapy Used in Cancer Treatment. |
| Q91734216 | Gene Therapy for Neurologic Disease: A Neurosurgical Review |
| Q40070708 | Gene Therapy in the Nervous System: Failures and Successes. |
| Q35870475 | Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models |
| Q36532106 | Gene therapeutics: the future of brain tumor therapy? |
| Q35118933 | Gene therapy and targeted toxins for glioma |
| Q57006162 | Gene therapy and targeted toxins for glioma |
| Q37804933 | Gene therapy and virotherapy: novel therapeutic approaches for brain tumors |
| Q34980337 | Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside |
| Q26829086 | Gene therapy for brain tumors: basic developments and clinical implementation |
| Q35040146 | Gene therapy for cancer treatment: past, present and future |
| Q35673628 | Gene therapy for malignant glioma |
| Q36226708 | Gene therapy for malignant glioma: current clinical status |
| Q36922247 | Gene therapy of gynaecological diseases |
| Q35880459 | Gene therapy trials for the treatment of high-grade gliomas |
| Q51467919 | Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells. |
| Q36345439 | Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q42135456 | Gene- and viral-based therapies for brain tumors |
| Q36247099 | Genetic strategies for brain tumor therapy |
| Q38225874 | Glioblastoma multiforme: State of the art and future therapeutics |
| Q42284122 | Glioblastoma: bridging the gap with gene therapy |
| Q37580510 | Glioma virus therapies between bench and bedside |
| Q36540199 | High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. |
| Q33262597 | Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. |
| Q31023442 | Human gene therapy and imaging in neurological diseases |
| Q39168899 | Immune and viral therapies for malignant primary brain tumors |
| Q36498773 | Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions |
| Q37245006 | Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain |
| Q40086745 | Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas |
| Q36274402 | Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. |
| Q33410559 | Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide |
| Q40384053 | In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine |
| Q57020987 | In vivo methods for acute modulation of gene expression in the central nervous system |
| Q45882637 | Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy |
| Q35285768 | Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus |
| Q38218094 | Influence of drugs on gap junctions in glioma cell lines and primary astrocytes in vitro |
| Q39678222 | Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma |
| Q36909502 | Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells |
| Q45866775 | Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. |
| Q33950709 | Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors |
| Q37998570 | Molecular neurosurgery: vectors and vector delivery strategies |
| Q90220710 | Nanomaterial-based blood-brain-barrier (BBB) crossing strategies |
| Q37591425 | Neuro-oncology: The long and winding road--gene therapy for glioma |
| Q34480167 | New Variants of Tomato Thymidine Kinase 1 Selected for Increased Sensitivity of E. coli KY895 towards Azidothymidine |
| Q50091640 | Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer |
| Q90668015 | Not gene therapy, but genetic surgery-the right strategy to attack cancer |
| Q33871577 | Novel immunotherapy clinical trials in malignant pleural mesothelioma |
| Q40064850 | Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer |
| Q80490182 | Oncolytic measles virus strains in the treatment of gliomas |
| Q36634430 | Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice |
| Q36498762 | One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. |
| Q35870480 | Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro |
| Q34205208 | Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol |
| Q34208293 | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma |
| Q35127438 | Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. |
| Q28550404 | Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase |
| Q37150860 | Prodrug approaches for CNS delivery |
| Q35155376 | Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis |
| Q38100997 | Progress in gene therapy for neurological disorders. |
| Q35069550 | Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. |
| Q48692331 | Radiolabeling strategies for radionuclide imaging of stem cells |
| Q35665065 | Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera |
| Q33573762 | Recent trends in targeted anticancer prodrug and conjugate design |
| Q36668246 | Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates |
| Q36740254 | SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors |
| Q36534329 | Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial |
| Q37818222 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma |
| Q39347239 | Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors |
| Q34012284 | Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma |
| Q97543045 | Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects |
| Q36166582 | Surgery for malignant gliomas: mechanistic reasoning and slippery statistics |
| Q30838365 | Surgical management of high-grade glioma: a standard of care |
| Q39084406 | The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells |
| Q30809060 | The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma |
| Q36527593 | The art of gene therapy for glioma: a review of the challenging road to the bedside |
| Q40386087 | The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context |
| Q92029579 | The cell-based approach in neurosurgery: ongoing trends and future perspectives |
| Q41134396 | The design and optimization of RNA trans-splicing molecules for skin cancer therapy. |
| Q24651009 | The status of gene therapy for brain tumors |
| Q37124552 | The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma |
| Q37338427 | Therapeutic nanomedicine for brain cancer |
| Q38438091 | Therapeutic potential of adenovirus-mediated delivery of β-defensin 2 for experimental otitis media |
| Q34295186 | Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis |
| Q34459264 | Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase |
| Q40148472 | Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma |
| Q39246483 | Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. |
| Q34674065 | Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression |
| Q37687420 | Viral vector-mediated gene transfer for CNS disease |
| Q37946113 | Viral vectors for gene delivery to the central nervous system |
| Q37567452 | Viruses, gene therapy and stem cells for the treatment of human glioma. |
| Q31156729 | Water spin dynamics during apoptotic cell death in glioma gene therapy probed by T1rho and T2rho |
| Q49118649 | YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. |
| Q55463952 | [Local therapy of primary brain tumors]. |
Search more.